Clearmind Medicine to Host ‘Psychedelics for Alcoholism‘ Virtual Educational Event on October 20
Anexpert panel will present and discuss new potential treatments for Alcohol UseDisorder and binge drinking
TORONTO,Oct. 1, 2021—via InvestorWire – Clearmind Medicine Inc. (CSE:CMND) (“Clearmind” or the “Company“), a psychedelicmedicine biotech company focused on the discovery and development of novelpsychedelic-derived therapeutics to solve widespread and undertreated healthproblems, is pleased to announce it will be hosting Psychedelics ForAlcoholism, a free, live virtual event highlighting new potentialtreatments for alcohol use disorder and binge drinking.
The online event will be held Oct. 20, 2021, starting at 12 p.m.EST/9 a.m. PST; registration is open and free to all. The event will includebrief presentations by featured speakers, followed by a discussion with aquestion-and-answer session.
The Company has curated a panel of scientists, thought leaders,therapists, and pundits to sharetheir experiences and educate participants on the mounting evidence suggestingthe effectiveness of psychedelics, and specifically MEAI, in the regulation ofexcessive drinking .
Representatives from the Company will also provide an updateon Clearmind’s MEAI-based medicines and their potential for the treatment ofAlcohol Use Disorder and binge drinking.
AdiZuloff-Shani, Ph.D., CEO of Clearmind, stated, “We’re in the middle of a PsychedelicRenaissance that is revolutionizing the way we treat mental disorders. We putthis event together to increase awareness of the advances being made in thefield, and more specifically generate awareness of the work Clearmind is doingwith regard to alcohol use and binge drinking.”
“Togetherwith our sponsors and partners, we are eager to share our progress and provideaccess to accurate information to interested communities, including mentalhealth practitioners, researchers, potential patients, investors and thegeneral public,” Zuloff-Shaniconcluded.
Following is a list ofour panelists and partners. To register for the event, or learn more aboutPsychedelics for Alcoholism, visit the event website.
Among our featured speakers and panelists: Shannon Smadella, moderator; Adi Zuloff-Shani, Ph.D., chief executive officer at Clearmind; Mark Haden, Advisory Board member,Clearmind; Terri Freeland, construction industry professional; and Dr. JeffMorley, registered psychologist.
Partners include: Canadian Psychedelic Association, WorldPsychedelics Day, McKennaAcademy of Natural Philosophy™, and Insight Global.
About Clearmind Medicine Inc.
Clearmind (CSE: CMND) is a psychedelicpharmaceutical biotech company focused on the discovery and development ofnovel psychedelic-derived therapeutics to solve widespread and underservedhealth problems, including alcohol use disorder. Its primary objective is toresearch and develop psychedelic-based compounds and attempt to commercializethem as regulated medicines, foods or supplements.
The Company’s intellectual portfoliocurrently consists of two patent families. The first, “Binge BehaviorRegulators,” has been granted in the U.S., Europe, China and India, withpending divisional applications in Europe and the U.S. The second, “AlcoholBeverage Substitute,” has been approved for a European patent, with pendingapplications in the U.S., China and India. The Company intends to seekadditional patents for its compounds whenever warranted and will remainopportunistic regarding the acquisition of additional intellectual property tobuild its portfolio.
Shares of Clearmind are listed fortrading on the Canadian Securities Exchange under the symbol “CMND“and the Frankfurt Stock Exchange under the symbol “CWYO”.
For further information, pleasecontact:
Investor Relations Email:
Telephone: (778) 400-5347
General Inquiries Email:
FORWARD-LOOKINGSTATEMENTS:
Thisnews release may contain forward-looking statements and information based oncurrent expectations. These statements should not be read as guarantees offuture performance or results. Such statements involve known and unknown risks,uncertainties and other factors that may cause actual results, performance orachievements to be materially different from those implied by such statements.Such statements include submission of the relevant documentation within therequired timeframe to the satisfaction of the relevant regulators and raisingsufficient financing to complete the Company’s business strategy. There is nocertainty that any of these events will occur. Although such statements arebased on management’s reasonable assumptions, there can be no assurance thatsuch assumptions will prove to be correct. We assume no responsibility toupdate or revise them to reflect new events or circumstances.
Investinginto early-stage companies inherently carries a high degree of risk, andinvestment into securities of the Company shall be considered highlyspeculative.
Thispress release shall not constitute an offer to sell or the solicitation of anoffer to buy, nor shall there be any sale of, the securities in any province inwhich such offer, solicitation or sale would be unlawful. The securitiesissued, or to be issued, under the Private Placement have not been, and willnot be, registered under the United States Securities Act of 1933, as amended,and may not be offered or sold in the United States absent registration or anapplicable exemption from registration requirements.
Neitherthe Canadian Securities Exchange (the “CSE”) nor its Regulation ServicesProvider (as that term is defined in the policies of the CSE) acceptsresponsibility for the adequacy or accuracy of this release.
WireService Contact
InvestorWire (IW)
Los Angeles, California
www.InvestorWire.com
212.418.1217 Office
Editor@InvestorWire.com